Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and 2.00% Convertible Notes Due 2032
Viking Therapeutics announced on Thursday, September 24, 2026 that it priced 7,857,143 shares of common stock at $35.00 per share (about $275 million) and $225.0 million of 2.00% convertible senior notes due October 15, 2032, after proposing the offerings on September 23. The notes convert at about $50.75 per share, roughly a 45% premium to the stock price, and underwriters have options on another 1,178,571 shares and $33.75 million of notes. Viking estimates net proceeds of about $258.2 million from the stock and $218.0 million from the notes, for its VK2735 and VK3019 programs and general purposes. The offerings are expected to settle on September 25, three days after Viking reported VK2735 maintenance-study results.